Wells Fargo & Company Theravance Biopharma, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TBPH
# of Institutions
133Shares Held
48.6MCall Options Held
13.9KPut Options Held
3.1K-
Madison Avenue Partners, LP New York, NY8.51MShares$69.9 Million12.2% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$61.2 Million3.74% of portfolio
-
Seth Klarman Baupost Group LLC | Boston, Ma4.2MShares$34.5 Million0.98% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$31 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$22.7 Million2.86% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $548M
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...